Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report

Medicina (Kaunas). 2021 Jan 24;57(2):104. doi: 10.3390/medicina57020104.


Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease.

Keywords: Charcot-Marie-Tooth disease type 2; IL-6; epigallocatechin gallate; motor activity; paraoxonase 1.

Publication types

  • Case Reports

MeSH terms

  • Aryldialkylphosphatase
  • Catechin / analogs & derivatives*
  • Charcot-Marie-Tooth Disease* / drug therapy
  • Female
  • Hand Strength
  • Humans
  • Male
  • Walk Test


  • Catechin
  • epigallocatechin gallate
  • Aryldialkylphosphatase
  • PON1 protein, human